Amneal Pharmaceuticals NY LLC received U.S. approval on Tuesday for its generic version of the transdermal opioid buprenorphine film, marking a new offering to a market currently dominated by Mallinckrodt's Solodyne patches. This entry grows competition within the generic transdermal space, potentially pressuring pricing across the segment as manufacturers vie for share of the $1.26 billion annual market.